Intriguingly, the expressions of all immune checkpoint molecules in the high-risk group were greater than that of another group, except for CD47 (Figure 6A, p < 0.05), suggesting that high-risk ovarian cancer patients might be more likely to benefit from immunotherapy. This evidence concerns the gene CD47 and ovarian carcinoma.